Production (Stage)
Perspective Therapeutics, Inc.
CATX
$2.39
-$0.12-4.78%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 342.00K | 234.00K | 369.00K | 526.00K | 325.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 342.00K | 234.00K | 369.00K | 526.00K | 325.00K |
| Cost of Revenue | 13.44M | 39.43M | -- | -- | 7.19M |
| Gross Profit | -13.09M | -38.96M | 369.00K | 526.00K | -6.86M |
| SG&A Expenses | 7.84M | 8.25M | 6.98M | 5.51M | 5.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.17M | 21.13M | 19.00M | 14.79M | 13.33M |
| Operating Income | -21.83M | -20.90M | -18.63M | -14.26M | -13.01M |
| Income Before Tax | -18.18M | -42.21M | -15.12M | -11.28M | -11.83M |
| Income Tax Expenses | -- | -2.10M | -- | -- | -- |
| Earnings from Continuing Operations | -18.18M | -40.11M | -15.12M | -11.28M | -11.83M |
| Earnings from Discontinued Operations | -- | -59.00K | -- | -429.00K | -459.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.18M | -40.17M | -15.12M | -11.70M | -12.28M |
| EBIT | -21.83M | -20.90M | -18.63M | -14.26M | -13.01M |
| EBITDA | -21.10M | -40.38M | -17.97M | -13.69M | -12.65M |
| EPS Basic | -0.25 | -0.57 | -0.21 | -0.18 | -0.25 |
| Normalized Basic EPS | -0.16 | -0.16 | -0.13 | -0.11 | -0.15 |
| EPS Diluted | -0.25 | -1.14 | -0.21 | -0.18 | -0.25 |
| Normalized Diluted EPS | -0.16 | -0.16 | -0.13 | -0.11 | -0.15 |
| Average Basic Shares Outstanding | 72.36M | 70.82M | 70.63M | 66.65M | 49.51M |
| Average Diluted Shares Outstanding | 72.36M | 70.82M | 70.63M | 66.65M | 49.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |